Pfizer COVID-19 vaccine promising

Pfizer COVID-19 vaccine promising
Colin Kerr
Colin Kerr
Published: Sunday, November 15, 2020
Pfizer and its collaborator, BioNTech have announced positive efficacy results from their Phase 3, late-stage study of their potential COVID-19 vaccine. The announcement, issued on Monday November 12, 2020 vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. "The results demonstrate that our mRNA-based vaccine can help prevent COVID-19 in the majority of people who receive it. This means we are one step closer to potentially providing people around the world with a much-needed breakthrough to help bring an end to this global pandemic," said Alfred Bourla,Chairman and Chief Executive Officer, Pfizer. "This is a first but critical step in our work to deliver a safe and effective vaccine," said Dr Bourla. https://www.pfizer.com/news/hot-topics/albert_bourla_discusses_covid_19_vaccine_efficacy_results On 1 April 2020, EuroTimes reported that Pfizer was teaming up with BioNTech to rapidly develop the Mainz, Germany-based firm’s BNT162, a messenger RNA-based potential vaccine for COVID-19. https://www.eurotimes.org/pfizer-biontech-target-april-vaccine-trial-launch/ The compound was expected to enter clinical testing by the end of April 2020, according to the two companies. If successful, it would prevent contraction of COVID-19 in patients not previously exposed to the SARS-Cov-2 coronavirus that causes the disease. BNT162 builds on BioNTech’s 2018 research and development collaboration with Pfizer to develop mRNA-based influenza vaccines. The method does not use neutralised virus to prompt host immune systems to develop antibodies to the live disease virus, as with traditional vaccines. Instead, mRNA from the virus is used to produce proteins in the body that are similar enough to the target virus to stimulate production of antibodies that will attack the actual virus should it appear.
Tags: pfizer covid 19
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...